Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Shuttle Pharmaceuticals Holdings, Inc. SHPH

Healthcare  —  Drug Manufacturers Specialty & Generic
4.01 0.01 0.25% as of 25 Sep
Market cap
$15.6M
P/E
34.7×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) Business Profile

Updated before January 2025

Company Overview

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is a clinical-stage pharmaceutical company specializing in the development of novel therapies to improve cancer treatment outcomes. Founded in 2012 and headquartered in Rockville, Maryland, SHPH was established by a team of experienced oncologists, radiologists, and pharmaceutical experts. The company’s mission is to leverage its expertise in radiation therapy and oncology to develop innovative solutions that enhance the effectiveness of cancer treatments while minimizing side effects.

The leadership team at SHPH includes Dr. Anatoly Dritschilo, who serves as the Chairman and CEO. Dr. Dritschilo is a renowned expert in radiation oncology and has been instrumental in driving the company’s research and development efforts. The management team also includes other seasoned professionals with extensive experience in the pharmaceutical and biotechnology sectors, ensuring a strong foundation for the company’s growth and innovation.

Core Business Segments

Shuttle Pharmaceuticals Holdings, Inc. operates primarily in the oncology sector, focusing on the development of drugs and therapies that enhance the efficacy of radiation therapy. The company’s core business segments include:

1. Radiation Sensitizers

Radiation sensitizers are a key area of focus for SHPH. These are drugs designed to make cancer cells more susceptible to radiation therapy, thereby improving treatment outcomes. SHPH’s lead product candidate in this category is Ropidoxuridine, an orally administered prodrug of iododeoxyuridine. Ropidoxuridine is currently in clinical trials and has shown promise in enhancing the effectiveness of radiation therapy for various types of cancer.

2. Immune Modulators

SHPH is also developing immune modulators that work in conjunction with radiation therapy to stimulate the immune system’s response to cancer. These therapies aim to improve the overall efficacy of cancer treatments by leveraging the body’s natural defense mechanisms.

3. Precision Diagnostics

In addition to therapeutic products, SHPH is investing in precision diagnostics to identify patients who are most likely to benefit from its therapies. By using biomarkers and advanced diagnostic tools, the company aims to personalize cancer treatment and improve patient outcomes.

Business Model

Shuttle Pharmaceuticals Holdings, Inc. operates on a business model that integrates research, development, and commercialization of innovative cancer therapies. The company generates revenue through licensing agreements, partnerships with healthcare providers, and eventual commercialization of its products. SHPH collaborates with academic institutions, research organizations, and pharmaceutical companies to accelerate the development and deployment of its therapies.

The company’s approach emphasizes a strong pipeline of proprietary products, supported by robust clinical trials and regulatory approvals. By focusing on niche areas such as radiation sensitizers and immune modulators, SHPH aims to carve out a unique position in the oncology market.

Strategic Direction

Shuttle Pharmaceuticals Holdings, Inc. has outlined a strategic roadmap to drive its growth and innovation in the coming years. Key elements of the company’s strategic direction include:

  • Expansion of Product Pipeline: SHPH is committed to advancing its existing product candidates through clinical trials while exploring new therapeutic areas and indications.
  • Global Partnerships: The company aims to establish strategic partnerships with international pharmaceutical companies to expand its market reach and accelerate product development.
  • Sustainability Goals: SHPH is focused on developing therapies that not only improve patient outcomes but also reduce the environmental impact of cancer treatments.
  • Investment in Research and Development: The company plans to allocate significant resources to R&D activities, ensuring a steady flow of innovative products and solutions.

Competitive Landscape

Shuttle Pharmaceuticals Holdings, Inc. operates in a highly competitive oncology market, facing competition from both established pharmaceutical giants and emerging biotech companies. Key competitors include:

  • AstraZeneca: Known for its oncology portfolio, including radiation sensitizers and immune-oncology therapies.
  • Merck & Co.: A leader in immune-oncology with its blockbuster drug Keytruda.
  • Eli Lilly and Company: Focused on developing targeted cancer therapies.
  • Smaller Biotech Firms: Companies such as Nanobiotix and OncoSec Medical are also exploring innovative approaches to enhance radiation therapy.

Despite the competition, SHPH differentiates itself through its specialized focus on radiation sensitizers and its commitment to personalized medicine.

Risk Factors

Like any pharmaceutical company, Shuttle Pharmaceuticals Holdings, Inc. faces several risks that could impact its operations and financial performance. Key risk factors include:

  • Regulatory Challenges: The company’s products must undergo rigorous clinical trials and obtain regulatory approvals, which can be time-consuming and costly.
  • Market Dependence: SHPH’s success is heavily reliant on the commercial success of its lead product candidates.
  • Supply Chain Disruptions: Any disruptions in the supply chain for raw materials or manufacturing processes could delay product development and commercialization.
  • Competition: The oncology market is highly competitive, and the entry of new players or products could impact SHPH’s market share.
  • Financial Risks: As a clinical-stage company, SHPH may face challenges in securing adequate funding to support its operations and R&D activities.

Recent Developments

Shuttle Pharmaceuticals Holdings, Inc. has made significant strides in recent months, including:

  • Advancement of Clinical Trials: The company has progressed its lead product candidate, Ropidoxuridine, into advanced stages of clinical trials, demonstrating promising results in enhancing radiation therapy.
  • Partnerships and Collaborations: SHPH has entered into strategic partnerships with academic institutions and research organizations to accelerate its R&D efforts.
  • Corporate Strategies: The company has implemented cost optimization measures and streamlined its operations to improve efficiency and focus on core business areas.

Investment Considerations

For investors considering Shuttle Pharmaceuticals Holdings, Inc., the following strengths and risks should be taken into account:

Strengths

  • Innovative Product Pipeline: SHPH’s focus on radiation sensitizers and immune modulators positions it as a leader in niche areas of oncology.
  • Experienced Leadership: The company’s management team brings extensive expertise in oncology and pharmaceutical development.
  • Strategic Partnerships: Collaborations with academic and research institutions enhance the company’s R&D capabilities.

Risks

  • Clinical and Regulatory Uncertainty: The success of SHPH’s products depends on the outcomes of clinical trials and regulatory approvals.
  • Financial Dependence: As a clinical-stage company, SHPH relies on external funding to support its operations.
  • Market Competition: The oncology market is highly competitive, with numerous players vying for market share.

Conclusion

Shuttle Pharmaceuticals Holdings, Inc. is a promising player in the oncology sector, leveraging its expertise in radiation therapy to develop innovative cancer treatments. While the company faces challenges typical of clinical-stage pharmaceutical firms, its strong product pipeline, experienced leadership, and strategic partnerships position it for long-term growth. As SHPH continues to advance its therapies and expand its market presence, it holds significant potential for improving cancer treatment outcomes and delivering value to investors.